TrovaGene, Inc. (TROV): Price and Financial Metrics

TrovaGene, Inc. (TROV): $1.19

0.01 (-0.83%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add TROV to Watchlist
Sign Up

Industry: Medical - Diagnostics/Research

Industry

NR

Ranked


in industry

TROV Price/Volume Stats

Current price $1.19 52-week high $3.46
Prev. close $1.20 52-week low $0.70
Day low $1.16 Volume 166,400
Day high $1.19 Avg. volume 648,892
50-day MA $1.05 Dividend yield N/A
200-day MA $1.47 Market Cap 13.10M

TROV Stock Price Chart Interactive Chart >


TrovaGene, Inc. (TROV) Company Bio


Trovagene, Inc. focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. The company was founded in 1999 and is based in San Diego, California.


TROV Latest News Stream


Event/Time News Detail
Loading, please wait...

TROV Latest Social Stream


Loading social stream, please wait...

View Full TROV Social Stream

Latest TROV News From Around the Web

Below are the latest news stories about Trovagene Inc that investors may wish to consider to help them evaluate TROV as an investment opportunity.

Trovagene Announces First Quarter 2020 Results and Highlights

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today announced company highlights and financial results for the first quarter ended March 31, 2020. The company is issuing this press release in lieu of conducting a conference call.

Yahoo | May 7, 2020

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

SAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant…

PR Newswire | May 6, 2020

Trovagene Announces Fourth Quarter and Full-Year 2019 Results

SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today…

PR Newswire | February 27, 2020

Trovagene Receives Approximately $1.45 Million From Exercise of Warrants

SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,…

PR Newswire | January 29, 2020

Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH

SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today…

PR Newswire | December 9, 2019

Read More 'TROV' Stories Here

TROV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -68.27%
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -60.63%

Continue Researching TROV

Here are a few links from around the web to help you further your research on Trovagene Inc's stock as an investment opportunity:

Trovagene Inc (TROV) Stock Price | Nasdaq
Trovagene Inc (TROV) Stock Quote, History and News - Yahoo Finance
Trovagene Inc (TROV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!